Correction to: Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy.

In the original publication of this article [1], there is an error in Fig. 4A.

Correction to: J Exp Clin Cancer Res

https://doi.org/10.1186/s13046-019-1072-8

In the original publication of this article [1], there is an error in Fig. 4A.

Fig. 4

Bazedoxifene inhibits induction of STAT3 phosphorylation and cell proliferation by IL-11. a: DLD-1, HCT-116, and HCT-15 cells were starved in serum-free medium for 24 h and pre-treated with bazedoxifene (5~20 μM) for 2 h. Then, 50 ng/ml (DLD-1 cells) or 25 ng/ml IL-11 (HCT-116 and HCT-15 cells), 50 ng/ml OSM (DLD-1 cells) and 50 ng/ml IFN-γ (DLD-1 cells) were added for stimulation. The p-STAT3Y705, p-STAT1Y701, STAT3, STAT1 and GAPDH were assessed by western blot analysis.

The corrected Fig. 4A should be: